实用医学杂志 ›› 2022, Vol. 38 ›› Issue (23): 3017-3022.doi: 10.3969/j.issn.1006⁃5725.2022.23.023

• 综述 • 上一篇    下一篇

放疗联合免疫治疗在非小细胞肺癌中的研究进展

李思玲 商凯 黄鸿翔 陈丽   

  1. 南昌大学第一附属医院肿瘤医学中心(南昌330000)

  • 出版日期:2022-12-10 发布日期:2022-12-10
  • 通讯作者: 陈丽 E⁃mail:33993051@qq.com

Research progress of radiotherapy combined with immunotherapy in non ⁃ small cell lung cancer

LI Siling,SHANG Kai,HUANG Hongxiang,CHEN Li.   

  1. The First Affiliated Hospital of Nanchang University,Nanchang 330000,China

  • Online:2022-12-10 Published:2022-12-10
  • Contact: CHEN Li E⁃mail:33993051@qq.com

摘要:

近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)发展迅速,但单药治疗时获益人群有限。基于放疗和 ICIs 的协同作用机制,以及 PACIFIC 研究的阳性试验结果,一系列关于放疗联合免疫治疗(combined radiotherapy and immunotherapy,IRT)的临床研究在非小细胞肺癌(non⁃small cell lung cancer,NSCLC)中相继展开并取得满意的结果,但研究组合形式各异,对于最佳组合方案仍无定论。本文将系统总结该治疗模式的联合作用机制、最新临床研究进展及相关研究热点问题,以期为 IRT 模式在
NSCLC 中的临床应用提供参考。

关键词: 非小细胞肺癌, 放射治疗, 免疫检查点抑制剂

Abstract:

Immune checkpoint inhibitors(ICIs)have rapidly developed in recent years,but the benefit of monotherapy is limited. On account of the synergistic mechanism between radiotherapy and ICIs,as well as the suc⁃ cessful clinical trial results of PACIFIC,a series of clinical studies on radiotherapy combined with immunotherapy (IRT)have been conducted in non⁃small cell lung cancer(NSCLC)and have yielded satisfactory results. However the best combination strategy is still up for debate because the research combinations vary. Here we summarize our understanding of the synergistic mechanisms of IRT and review the most recent advances in development and hot⁃button issues in relevant clinical research in order to provide a reference for the clinical application of the IRT model in NSCLC. 

Key words:

non?small cell lung cancer, radiotherapy, immune checkpoint inhibitors